1 day Ago By ABMN Staff
Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) ‘s stock had its “overweight” rating reaffirmed by stock analysts at Cantor Fitzgerald in a report issued on Monday, Benzinga reports. They presently have a $107.00 target price on the stock.
Cantor Fitzgerald’s price target would suggest a potential upside of 17.66% from the stock’s current price. Several other research firms also recently commented on AXSM.
Mizuho reissued a “buy” rating and issued a $106.00 target price on shares of Axsome Therapeutics in a report on Wednesday, June 12th. UBS Group dropped their price target on shares of Axsome Therapeutics from $107.
00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, August 6th. Royal Bank of Canada reduced their price objective on shares of Axsome Therapeutics from $131.
00 to $130.00 and set an “outperform” rating for the company in a research note on Tuesday, August 6th. Needham & Company LLC reiterated a “buy” rating and issued a $130.
00 target price on shares of Axsome Therapeutics in a research note on Thursday, September 5th. Finally, Bank of America raised Axsome Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $95.00 to $106.
00 in a report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $124.
57. Check Out Our Latest Report on Axsome Therapeutics Axsome Therapeutics Trading Down 1.6 % Axsome Therapeutics ( NASDAQ:AXSM – Get Free Report ) last released its quarterly earnings results on Monday, August 5th.
The company reported ($1.24) EPS for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.
06. Axsome Therapeutics had a negative return on equity of 117.46% and a negative net margin of 105.
85%. The business had revenue of $87.17 million during the quarter, compared to analyst estimates of $84.
53 million. As a group, sell-side analysts forecast that Axsome Therapeutics will post -4.73 EPS for the current year.
Insiders Place Their Bets In other news, Director Mark E. Saad sold 11,016 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was sold at an average price of $91.
31, for a total transaction of $1,005,870.96. Following the sale, the director now owns 10,002 shares in the company, valued at $913,282.
62. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink . In other news, COO Mark L.
Jacobson sold 47,739 shares of the stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $84.26, for a total value of $4,022,488.
14. Following the completion of the sale, the chief operating officer now directly owns 5,783 shares in the company, valued at $487,275.58.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, Director Mark E. Saad sold 11,016 shares of the company’s stock in a transaction on Wednesday, September 11th.
The shares were sold at an average price of $91.31, for a total value of $1,005,870.96.
Following the completion of the sale, the director now owns 10,002 shares of the company’s stock, valued at $913,282.62. The disclosure for this sale can be found here .
Corporate insiders own 22.40% of the company’s stock. Institutional Inflows and Outflows Large investors have recently bought and sold shares of the stock.
Vanguard Group Inc. raised its stake in shares of Axsome Therapeutics by 1.2% in the 1st quarter.
Vanguard Group Inc. now owns 3,740,278 shares of the company’s stock valued at $298,474,000 after acquiring an additional 43,512 shares during the period. Perceptive Advisors LLC increased its holdings in Axsome Therapeutics by 115.
5% in the 4th quarter. Perceptive Advisors LLC now owns 1,038,019 shares of the company’s stock valued at $82,616,000 after purchasing an additional 556,370 shares during the last quarter. Point72 Asset Management L.
P. increased its holdings in Axsome Therapeutics by 57.4% in the 4th quarter.
Point72 Asset Management L.P. now owns 837,201 shares of the company’s stock valued at $66,633,000 after purchasing an additional 305,264 shares during the last quarter.
Millennium Management LLC raised its position in Axsome Therapeutics by 1.4% in the second quarter. Millennium Management LLC now owns 739,819 shares of the company’s stock valued at $59,555,000 after purchasing an additional 10,401 shares during the period.
Finally, Bellevue Group AG lifted its stake in Axsome Therapeutics by 7.9% during the first quarter. Bellevue Group AG now owns 685,476 shares of the company’s stock worth $54,701,000 after purchasing an additional 50,104 shares in the last quarter.
Institutional investors and hedge funds own 81.49% of the company’s stock. About Axsome Therapeutics ( Get Free Report ) Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.
The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. Read More Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
